Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094913
Status:
UNKNOWN
Last Update Posted:
2009-05-27
First Post:
2004-10-28
Brief Title:
PET Changes in Alzheimers Disease AD
Sponsor:
National Institute on Aging NIA
Organization:
National Institute on Aging NIA
Study Overview
Official Title:
Clinical Correlates of Longitudinal PET Changes in Alzheimers Disease AD
Status:
UNKNOWN
Status Verified Date:
2007-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to identify the earliest predictors of memory and brain deterioration in pre-clinical Alzheimers disease using positron emission tomography PET to monitor brain glucose metabolism
Detailed Description:
Previous studies indicate that the brains glucose metabolism rate potentially may be an early indicator of damage to particular regions of the brain caused by AD including loss of neurons synapses and other changes Many of these changes are reported among patients with mild cognitive impairment MCI a group known to be at increased risk for AD
The overall goal of this study is to use FDG-PET 2-18Ffluoro-2-deoxy-d-glucosepositron-emission tomography to determine whether metabolic abnormalities in the hippocampus predict memory and brain deterioration in middle age and to identify the brain glucose metabolism predictors of future MCI
Participants in the study will be grouped into 3 main groups of 35 each including young individuals 20-40 years of age 41-90 year-old normal and MCI individuals with or without risk for memory decline Participants will undergo baseline and 36-month follow-up exams to include comprehensive medical neurologic and psychiatric evalutions lumbar puncture a resting FDG-PET an MRI scan and a neuropsychological battery A brief medical exam full neuropsychological battery and MRI scan will be administered at 18 months Two subgroups groups 4 and 5 of 15 each will be created from groups 1 and 2 at 18 months to participate in the evaluation of memory performance under acute hyperglycemia and saline challenges and effects on hippocampal formation and glucose metabolism
The overall goal of this study is to use FDG-PET 2-18Ffluoro-2-deoxy-d-glucosepositron-emission tomography to determine whether metabolic abnormalities in the hippocampus predict memory and brain deterioration in middle age and to identify the brain glucose metabolism predictors of future MCI
Participants in the study will be grouped into 3 main groups of 35 each including young individuals 20-40 years of age 41-90 year-old normal and MCI individuals with or without risk for memory decline Participants will undergo baseline and 36-month follow-up exams to include comprehensive medical neurologic and psychiatric evalutions lumbar puncture a resting FDG-PET an MRI scan and a neuropsychological battery A brief medical exam full neuropsychological battery and MRI scan will be administered at 18 months Two subgroups groups 4 and 5 of 15 each will be created from groups 1 and 2 at 18 months to participate in the evaluation of memory performance under acute hyperglycemia and saline challenges and effects on hippocampal formation and glucose metabolism
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01AG013616 | NIH | None | httpsreporternihgovquickSearchR01AG013616 |